Vivos Therapeutics Inc VVOS trimmed operating costs and grew service revenue while flagging substantial doubt about its ability to continue as a going concern.
Why Is Vivos Therapeutics, Inc. (VVOS) Stock Down Today?
Updated Nov 22, 2026 6:09 AM ET ยท Prev Close $0.06
Session Regime & Catalyst Assessment
68% Signal ConvictionVivos Therapeutics, Inc. Pulling Back 5.10% on 1.19x Relative Volume
Vivos Therapeutics, Inc. (VVOS) is pulling back 5.10% (+$0.00) to $0.05 on 1.19x average session volume. Relative to benchmarks, VVOS is lagging the S&P 500 by -1.46%. 14-day RSI stands at 18.9, keeping momentum in a oversold regime.
Vivos Therapeutics Inc VVOS trimmed operating costs and grew service revenue while flagging substantial doubt about its ability to continue as a going concern.
Price ($0.05) trades relative to 20-day SMA ($0.10) and 50-day SMA ($0.13).
Market & Sector Relative Strength
VVOS lagging the S&P 500 by -1.46%Options Flow & Execution Desk
Recent VVOS Catalyst Headlines
Verified WireVivos Therapeutics VVOS delivered earnings and revenue surprises of 76.67 and 17.15 , respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Revenue rises 24 quarter over quarter as Third quarter operating loss improves 18 year over year on cost reductions Company regained compliance with Nasdaq stockholders equity requirement Management to Host Conference Ca
This release removes the mention of Cleveland Clinic Weston.Partnership unites the ReBalU Protocol, Vivos's sleep platform, and a new test for cells primed for chronic disease, reaching nearly 500,000 chronic disease pat
1โ3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $0.05 (session support) for directional breakout confirmation.
Technical Regime (VVOS)
BEARISH MA TRENDRetail & Crowd Sentiment
BearishVivos Therapeutics reported a 24% increase in revenue for Q3 2026, with a reduced operating loss and cost savings. The company regained compliance with Nasdaq's stockholders' equity requirement.
About Vivos Therapeutics, Inc.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. โฆ
Get Instant VVOS Catalyst Alerts
Receive an email alert when VVOS triggers an unusual volume breakout, options sweep, or rating shift.
VVOS Session & Catalyst FAQ
Why is VVOS stock down today?
Vivos Therapeutics, Inc. (VVOS) is pulling back 5.10% (+$0.00) to $0.05 on 1.19x average session volume. Relative to benchmarks, VVOS is lagging the S&P 500 by -1.46%. 14-day RSI stands at 18.9, keeping momentum in a oversold regime.
Is VVOS stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 1.19x relative volume (moderate participation). Our multi-factor model currently rates VVOS as AVOID NEW MONEY. Review full valuation, quality, and timing signals on the VVOS Buy or Sell Decision Brief โ
What is VVOS's intrinsic value and expected trading range?
At $0.05, VVOS's modeled 1-to-3 session range is $0.05 โ $0.05, with a key inflection level at $0.05 (session support). Compare current price against multi-year cash flow projections in the VVOS Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
What do RSI and moving averages signal for VVOS?
RSI at 18.9 indicates oversold conditions โ watch for mean-reversion support. VVOS trades at $0.05 relative to its 20-day SMA ($0.10) and 50-day SMA ($0.13), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.